{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:16:30Z","timestamp":1775175390424,"version":"3.50.1"},"reference-count":0,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis"],"published-print":{"date-parts":[[2019]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Aims:&lt;\/i&gt;&lt;\/b&gt; Ascites is one of the major complications in advanced cirrhotic patients. Tolvaptan is a non-peptide orally available arginine vasopressin V2 receptor antagonist. We investigated and found that tolvaptan therapy improved the prognosis and predictive factor of cirrhotic patients with ascites. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; Overall, 99 patients with newly diagnosed ascites with cirrhosis were enrolled. No patients had intrahepatic malignancy. The patients were divided into 2 groups based on tolvaptan therapy: 86 patients treated with tolvaptan (tolvaptan-group) and 13 patients treated without tolvaptan (non-tolvaptan-group). Tolvaptan-responder was defined as body weight loss of \u22651.5 kg\/week after administering tolvaptan. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Tolvaptan therapy was effective in 61.6% of cirrhotic patients. There was a significant difference in the overall survival (OS) between the tolvaptan-responder-group and the other groups (&lt;i&gt;p&lt;\/i&gt; &amp;#x3c; 0.001). Male (HR 5.05; &lt;i&gt;p&lt;\/i&gt; = 0.01), tolvaptan responder (HR 0.21; &lt;i&gt;p&lt;\/i&gt; = 0.02), and dosage of furosemide &amp;#x3c; 40 mg\/day (HR 0.17; &lt;i&gt;p&lt;\/i&gt; = 0.01) were factors that were independently associated with the OS. The multivariate analysis revealed that C-reactive protein &amp;#x3c; 0.9 mg\/dL (HR 0.07; &lt;i&gt;p&lt;\/i&gt; = 0.001), and furosemide dosage &amp;#x3c; 40 mg\/day (HR 0.09; &lt;i&gt;p&lt;\/i&gt; = 0.003) were independently associated with the tolvaptan response. &lt;b&gt;&lt;i&gt;Conclusion&lt;\/i&gt;&lt;\/b&gt;: Therapeutic response to tolvaptan was associated with longer survival in cirrhosis patients complicated with ascites. These preliminary findings warrant validation and further exploration.<\/jats:p>","DOI":"10.1159\/000494438","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T22:05:44Z","timestamp":1547071544000},"page":"239-246","source":"Crossref","is-referenced-by-count":8,"title":["Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites"],"prefix":"10.1159","volume":"37","author":[{"given":"Yohei","family":"Kida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2019,1,9]]},"container-title":["Digestive Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/494438","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/494438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:04:33Z","timestamp":1745427873000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000494438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2,21]]}},"URL":"https:\/\/doi.org\/10.1159\/000494438","archive":["Portico"],"relation":{},"ISSN":["0257-2753","1421-9875"],"issn-type":[{"value":"0257-2753","type":"print"},{"value":"1421-9875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}